Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3077407 | 0.90 | MAPT (0.57) | HTR6ALDH1A1PKMMAPTGAA | |
| SCHEMBL30932826 | 0.90 | MAPT (0.57) | HTR6ALDH1A1PKMMAPTGAA | |
| SCHEMBL12639373 | 0.87 | MEN1 (0.62) | HTR6ALDH1A1PKMMAPTGAA | |
| SCHEMBL11112123 | 0.85 | CA12 (0.61) | HTR6ALDH1A1PKMMAPTGAA | |
| SCHEMBL3284674 | 0.84 | GAA (0.57) | HTR6ALDH1A1PKMMAPTGAA | |
| SCHEMBL2458633 | 0.82 | HTR6 (0.58) | HTR6ALDH1A1MAPTLMNASLC16A1 | |
| SCHEMBL950448 | 0.82 | HTR6 (0.74) | HTR6ALDH1A1PKMMAPTGAA | |
| SCHEMBL30166976 | 0.82 | HTR6 (0.74) | HTR6ALDH1A1PKMMAPTGAA | |
| SCHEMBL11325826 | 0.80 | PTGES2 (0.48) | HTR6MAPTGAANPSR1POLB | |
| SCHEMBL22557572 | 0.79 | HTR6 (0.48) | HTR6ALDH1A1PKMMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101208299-A | Diarylsulfone sulfonamides and use therof | WYETH CORP (US) | 2008-06-25 | — | — | CN | disclosed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
| EP-0617010-B1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2002-01-09 | — | — | EP | disclosed |
| US-5900432-A | Therapeutic N-(4-benzoyl-2-methyl-phenyl)-3,3,3-trifluoro-2-hydroxy-2-methyl-propanamides | ZENECA LIMITED (GB) | 1999-05-04 | — | — | US | disclosed |
| US-5700798-A | Methods for using benzoxazines for treating asthma | ZENECA LIMITED (GB) | 1997-12-23 | — | — | US | disclosed |
| EP-0698022-B1 | 1,4-BENZOXAZINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | ZENECA LTD (GB) | 1997-09-17 | — | — | EP | disclosed |
| EP-0698022-A1 | 1,4-BENZOXAZINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | ZENECA LTD (GB) | 1996-02-28 | — | — | EP | disclosed |
| US-5486515-A | 2-fluoroalkyl-1,4-benzoxaxines as potassium channel mediators | ZENECA LIMITED (GB) | 1996-01-23 | — | — | US | disclosed |
| US-5482969-A | Certain N(4-benzoyl-2-phenyl)-3- trifluoro-2-hydroxy-propanamide derivatives | ZENECA LIMITED (GB) | 1996-01-09 | — | — | US | disclosed |
| WO-1994026739-A1 | 1,4-BENZOXAZINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | ZENECA LIMITED (GB) | 1994-11-24 | — | — | WO | disclosed |
| EP-0617010-A1 | Therapeutic compounds | ZENECA LIMITED (GB) | 1994-09-28 | — | — | EP | disclosed |
| US-4754024-A | Fibre-reactive azo dyes containing vinylsulfonyl or analogous groups | CIBA-GEIGY CORPORATION | 1988-06-28 | — | — | US | disclosed |
| EP-0112285-B1 | REACTIVE DYES, THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1987-03-18 | — | — | EP | disclosed |
| EP-0112285-A2 | Reactive dyes, their preparation and their use | CIBA-GEIGY AG (CH) | 1984-06-27 | — | — | EP | disclosed |
| US-4370431-A | Process for coloring fibre forming polyamides in the melt with azo pigments | CIBA-GEIGY CORPORATION (US) | 1983-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | HTR6 3789/4885ALDH1A1 1865/4885PKM 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.